Corti Accelerates Healthcare AI Innovation with New Program

Corti, the Copenhagen-headquartered healthtech startup, has announced the launch of its Startup Acceleration Program, a no-equity initiative. This program is designed to offer healthcare AI builders worldwide access to the same clinical-grade models that power highly regulated systems across Europe and the US. The primary goal is to help founders ship and scale their solutions at a time when the regulatory bar for healthcare AI has never been higher.

The grant-funded program positions itself as a frontier lab for clinical-grade AI. Corti's flagship model, Symphony, already powers clinical and administrative applications for EHR vendors, virtual care platforms, practice management systems, and life sciences organizations globally, serving over 100 million patients annually, including those within the NHS.

The Regulatory Landscape: A Proving Ground for AI in Europe

The healthcare AI sector is facing an intensification of regulations across all major markets. From the FDA's expanded AI/ML guidance in the US to new lifecycle accountability requirements in Canada and the UK, the landscape is rapidly evolving. However, Europe emerges as the most acute case, with the introduction of the EU AI Act imposing stringent requirements for high-risk systems, with enforcement for medical AI anticipated by August 2, 2026.

This regulatory complexity has already had a significant impact. In the US, OpenAI rolled out free clinical AI for verified physicians, while in Europe, OpenEvidence, a clinical AI platform valued at $12 billion and used by 40% of US physicians, withdrew from the UK and European markets, citing regulatory uncertainty around the EU AI Act. Costs for EU MDR certification, for instance, can range from €200,000 to €600,000 per device and take 12 to 18 months, a factor that significantly impacts TCO and the innovation capacity of startups. This scenario is leading to a concentration of capital in larger, later-stage funding rounds, favoring companies with proven clinical evidence and integration into existing workflows.

Corti's Approach and Program Benefits

Andreas Cleve, co-founder and CEO of Corti, emphasizes that the future of healthcare AI will not be built by one company, but by thousands of teams with deep knowledge of specific care settings, workflows, or patient populations. Corti's role is to give these builders a head start: a leading clinical AI model, a robust evidence base, and a path to production already navigated for regulated health systems. This allows startups to focus on their distinctive competencies, such as specific workflows or patient needs.

The acceleration program includes up to $5,000 in credits across Corti's full Symphony stack (Agents, Medical Coding, Speech-to-Text, and Text Generation), built on over 1.5 million hours of clinical audio. It also offers support from Corti's clinical and regulatory team to navigate the complexities of the EU AI Act, MDR certification, and data residency requirements. Startups will also have access to Corti's AI experts to scope product roadmaps and architect systems before the development phase, in addition to webinars and invitations to exclusive events. Among the teams already building on Corti is Aisel Health, a European startup creating AI for psychiatry, highlighting how integration with existing platforms allows focus on specialized solutions.

Implications for Deployment and Data Sovereignty

The regulatory challenges and associated compliance costs underscore the importance of robust and compliant deployment strategies. For organizations operating in highly regulated sectors such as healthcare, data sovereignty and the ability to guarantee data residency are critical factors. The need to comply with regulations like the EU AI Act and GDPR often prompts companies to consider self-hosting or hybrid deployment options, where control over infrastructure and data is maximized.

Programs like Corti's, which offer regulatory support and access to pre-validated models, can significantly reduce risk and TCO for startups aiming to operate in these complex environments. The ability to leverage an already compliant clinical foundation allows teams to focus on domain-specific innovation, rather than rebuilding regulatory groundwork. For those evaluating on-premise deployments or hybrid solutions for AI/LLM workloads, AI-RADAR offers analytical frameworks on /llm-onpremise to assess the trade-offs between control, cost, and scalability in highly regulated contexts.